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ABSTRACT & KEY WORDS 
Objective: To assess the programmatic quality (coverage of testing, counselling and 
retesting), cost, and outcomes (viral suppression, treatment decisions), of routine viral load 
(VL) monitoring in Swaziland. 
Design: Retrospective cohort study of patients undergoing routine VL monitoring in 
Swaziland, 01/10/2012 to 31/03/2013.  
Results: Of 5563 patients eligible for routine VL testing monitoring in the period of study, an 
estimated 4767 patients (86%) underwent testing that year. Of 288 patients with detectable 
VL, 210 (73%) underwent enhanced adherence counselling, and 202 (70%) had a follow-up 
VL within 6 months. Testing coverage was slightly lower in children, but coverage of 
retesting was similar between and age groups and sexes. Of those with a follow-up test, 126 
(62%) showed viral suppression. The remaining 78 patients had WHO-defined virologic 
failure; 41 (53%) were referred by the doctor for more adherence counselling, and 13 (15%) 
were changed to second-line therapy, equating to an estimated rate of 1.2 switches per 100 
patient-years. Twenty-four patients (32%) were transferred out, lost to follow up or not 
reviewed by doctor. The ‘fully-loaded’ cost of VL monitoring was $35 per patient-year. 
Conclusions: Achieving good quality VL monitoring is feasible and affordable in resource-
limited settings, although close supervision is needed to ensure good coverage of testing and 
counselling. The low rate of switch to second-line therapy in patients with WHO-defined 
virologic failure seems to reflect clinician suspicion of ongoing adherence problems. In our 
study, the main impact of routine VL monitoring was reinforcing adherence rather than 
increasing use of second-line therapy. 
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Introduction 
The 2013 World Health Organisation (WHO) guidelines recommend routine viral load (VL)  
monitoring of all patients on Antiretroviral Therapy (ART) for more than six months, to 
enable earlier detection of treatment failure due to resistance mutations, and to help 
clinicians distinguish this from adherence problems.1  Since an elevated VL after six months 
on ART can indicate either therapeutic failure due to drug resistance or poor adherence to 
treatment, the WHO recommends that such patients receive adherence support followed by 
retesting at 3-6 months, at which time a  persistently elevated VL (>1000 copies/ml) should 
be considered as therapeutic failure requiring switch to second  line therapy.
1
 Although 
randomised controlled trials have so far failed to show survival benefits from VL monitoring, 
compared to immunological monitoring alone, programmatic research has shown that 
routine VL monitoring of patients on ART, with an adherence intervention for patients with 
detectable VL, is associated with improved treatment outcomes and earlier switches to 
second line therapy.2–4 
Routine VL monitoring is resource intensive, in terms of reagents and transport logistics. An 
efficient VL monitoring ‘cascade’ with minimal delays between steps is essential for VL 
monitoring to enable early intervention (either counselling or switch to second line therapy), 
in order to prevent further accumulation of mutations and disease progression associated 
with chronic viraemia.5 Thus, before rolling out such programmes nationwide, countries 
need to know how to establish good quality VL monitoring (in terms of coverage and time-
efficiency of testing, counselling, and retesting in all age groups).1 Furthermore, although VL 
monitoring is associated with superior programmatic outcomes, concerns have been 
expressed about the cost (and cost-effectiveness) of this monitoring strategy for low and 
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middle income countries.6 However, costs of viral load reagents are decreasing as demand 
for testing rises and more suppliers enter the market; since the cost of manufacture of 
reagents is relatively low, pooled purchasing by governments and major donors enables 
better price negotiation with the suppliers.7 The possibility of pooled sampling and other 
cost reduction strategies such as Dried Blood Spot sampling means that VL monitoring is 
quickly becoming accessible to lower resource countries.
 7
 
Implementation research on routine VL monitoring in resource-limited settings is still 
limited. Several studies have investigated virological outcomes following adherence 
counselling, although most of these studies focused on adults.
8
 In terms of impact on 
treatment decisions, existing studies suggest that many patients with virological failure 
identified through routine VL monitoring are not switched to second line therapy; rates of 
switch as low as 0.18% amongst routinely virologically monitored patients have been 
described.9,10 Furthermore, it is not clear that VL monitoring always leads to earlier switching 
to second line therapy; studies have reported ‘time to switch’ of over 16 months following 
VL testing.11,12 
Swaziland is one of several countries in sub-Saharan Africa that is planning to roll out routine 
VL monitoring.13,14 In 2012, the country started a pilot program of routine VL monitoring 
with enhanced adherence counselling (EAC) for patients with detectable VL, in one region of 
the country, supported by Médecins sans Frontières (MSF). No published studies document 
the feasibility and impact of VL monitoring in a rural setting comparable to Swaziland, with a 
highly decentralised health system and a low level of reported HIV drug resistance.15 
Furthermore, the Swaziland pilot program uses a generic VL platform (commercialised by 
Biocentric) to reduce costs; some authors have suggested that using generic platforms may 
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make VL monitoring affordable, and so obtaining ‘real time’ costing data in such programs is 
essential.16 
This study assesses the programmatic quality (coverage of testing and counselling), costs and 
impact (virological outcomes and treatment decisions), of routine VL monitoring in 
Swaziland. The rate of switches to second line therapy is  described, as well as the number 
and proportion of patients who are ‘lost’ at each step in the VL monitoring process. The 
study will thus inform the implementation approach for national roll-out and may assist 
other programs planning to introduce routine VL monitoring. 
AC
CE
PT
ED
Copyright   Lippincott Williams & Wilkins. All rights reserved.
 7 
Methods 
Design 
Retrospective cohort study using data from the pilot routine VL monitoring program in 
Shiselweni, Swaziland. 
Setting  
Swaziland is a landlocked lower-middle income country in Southern Africa, with a population 
of 1.2 million and an adult HIV prevalence of 31% (18-49 age group).9 Shiselweni (the study 
region) has a poor and rurally-located population, with approximately 37,000 people living 
with HIV, 15,800 of whom are on ART.
10
 ART is provided through a decentralised network of 
22 primary care clinics and three referral facilities; this has been achieved through task-
shifting of ART management from doctors to nurses. Médecins Sans Frontières (MSF) has 
supported these health facilities since 2007. 
Patients on ART in Swaziland undergo six-monthly immunological monitoring; the country 
also has VL testing capacity at its National Reference Laboratory, but until now this service is 
reserved for ‘targeted monitoring’ for patients with suspected treatment failure.  In 2012 
MSF, in collaboration with the Ministry of Health, implemented routine plasma-based VL 
monitoring throughout the Shiselweni region, using a Generic HIV VL platform (Biocentric, 
France) based at the regional virology laboratory; MSF provided laboratory equipment and 
reagents, logistic support, and training of nursing and counselling staff.  All patients on ART 
for at least six months are now offered annual VL monitoring, with enhanced adherence 
counselling (EAC) for patients with detectable VL. Full details of the programme and 
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monitoring algorithm can be found in Box S1 and Figure S1 (see Supplemental Digital 
Content, http://links.lww.com/QAI/A535).  
Participants 
The study population consisted of all patients on ART for at least six months (registered in 
the national ART database), attending Shiselweni primary healthcare clinics during the 
period 01 October 2012- 31 March 2013. Patients who underwent VL testing and had a 
detectable VL were followed up for a minimum of six months after the test. Patients who 
had undergone VL testing in the previous year were excluded. Patients attending secondary 
facilities were not included, since VL monitoring was not implemented in secondary facilities 
until early 2013.   
Data collection and validation 
The National ART Patient Monitoring Register (APMR) was used to identify patients 
attending primary care clinics in the study period. To assess coverage we linked the ART 
records of active patients with the VL laboratory records using a unique patient identifier 
(ART number).  
To address questions of programme quality we followed up a cohort of patients with 
detectable VL, for whom lab records showed that their first VL test occurred during the 
study period. An MSF data clerk accessed patient files in the health facilities to collect data 
on dates of EAC sessions, treatment decisions following VL monitoring, and other outcomes 
(death, loss to follow-up, transfer out or stopped ART). Clinic records were also used to 
determine when the health facility had received the test results. Since the patient normally 
receives their first EAC session on the day they receive a detectable VL result, the date of 
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first EAC session was used to estimate the turnover time from blood draw to receipt of result 
by the patient.  Information regarding patient follow-up and outcome was crosschecked 
with the doctors’ records of ‘at-risk’ patients (which include all paediatric HIV patients, all 
patients on 2
nd
 line ART, and all patients with detectable VL). 
Costing data included costs of reagents, laboratory staff, consumables, transport, equipment 
maintenance & depreciation, overheads, and construction depreciation. To enable 
comparison with the cost of CD4 monitoring, the same data was collected for point-of-care 
CD4 testing by PIMA, which is the primary means of CD4 quantification in the study setting. 
All data was obtained from accounting, invoices and interviews with MSF and Ministry of 
Health staff. Triangulation between sources, using top-down (empirical) and bottom-up 
(theoretical) approaches, was used to ensure accuracy of costing data.  
Data analysis 
Initial VL results were classified as “detectable” or “undetectable” according to the detection 
threshold of the Biocentric technique (100-400copies/ml). Follow-up VL results were 
classified as “suppressed” or “virologic failure”, with virologic suppression defined as VL 
below the therapeutic failure threshold (1000copies/ml) at least 60 days after an initial 
detectable VL.1 
Proportions were estimated for patients (1) Eligible for, and undergoing, VL testing (and 
their results), (2) Eligible for and undergoing EAC (and number of sessions received), and (3) 
Eligible for and undergoing retesting (and their results). Pearson’s Chi Square test (for 
categorical variables) and a non-parametric comparison of medians (for continuous 
variables) were used to check for statistically significant differences in these three outcomes 
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according to different subgroups of interest. The median time taken between each stage in 
the process was calculated, and presented with Inter-quartile ranges (IQRs). 
The rate of switch to a second line regimens is presented per 100 person-years, with the 
entry point determined as the date of blood draw for the initial VL, and the exit date being 
the switch date or the end of follow-up in the cohort study (the last date a data clerk 
retrieved the patient files to extract outcome data). We estimated an overall rate of switch 
to second line ART in patients undergoing routine VL monitoring using a proportionate 
random sample of undetectable first VL lab records from the same time period, applying the 
median follow-up time for the detectable cohort to each record, and assuming that none 
switched to second line therapy. 
An ingredient costing approach, by which the total ingredient costs over a one-year period 
were divided by the total number of tests done, was used to calculate the ‘fully-loaded’ cost 
of each VL and CD4 test. The annual cost per patient monitored was calculated separately 
for CD4 and VL monitoring, on the basis of the average number of tests per patient year 
(including EAC in the case of VL monitoring). 
Epidata 3.1 was used for data entry. Data management and statistical analysis was 
performed using Stata/SE (StataCorp, Texas, U.S.A.) Version 12.1. 
Ethics 
This study has received ethical approval from the MSF Ethics Review Board, Geneva, 
Switzerland, and the Swaziland Scientific and Ethics Committee, Mbabane, Swaziland. 
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Results 
Baseline characteristics of study population (table 1) 
In the study period, 6905 active patients on ART for over six months attended clinics in 
Shiselweni. Of these, 1342 (19%) individuals had already received a VL test in the previous 
year. The remaining 5563 patients were deemed eligible for VL testing, of whom 28 (0.5%) 
were on second line therapy. Baseline characteristics of eligible patients are given in Table 1.  
Coverage of testing (table 1) 
Of those eligible for VL testing, 1385 (25%) underwent testing within the six-month study 
period, and 1517 (27%) were tested in the subsequent six months (up to 30 September 
2013). An additional 2220 initial VL tests were sent from clinics during these 12 months, but 
could not be linked electronically with the patient records. 
There was no significant difference in testing coverage by sex, and the median time on ART, 
and median last CD4 were similar among those who were tested and those who were not 
tested. Testing coverage appeared to be lower in children compared to adults (p=0.0206).  
Coverage of counselling and retesting among patients with detectable VL (figure 1 & table 2) 
Laboratory records showed 3242 VL tests were carried out in clinics in the 6-month study 
period, 551 (17%) of which were detectable (figure 1). Of these, 288 (52%) were confirmed 
to be initial VL tests in eligible patients. These patients were followed up using all available 
clinical records including the patient files for a median of 7.6 months (IQR 6.2 – 9.2). From 
figure 1 it can be seen that 78 (27%) of these patients did not receive EAC. Fifty-eight (20%) 
received a complete EAC intervention of three sessions, and 152 (53%) received either one 
or two EAC sessions. There was no significant difference in coverage of EAC between sex and 
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age groups. The median VL was similar in the group that received EAC and the group that did 
not.  
In all, 202 (70%) of patients with initial detectable VL received a follow-up VL, with a median 
time from first VL of 4.6 months (IQR 3.4-6.2), and of these 126 (62%) showed viral 
suppression. There was no significant difference in coverage of retesting or proportion 
suppressing by age group or sex; median time on ART in those who suppressed was similar 
to that in the overall study population. The proportion undergoing follow-up testing was 
significantly higher in patients who had received at least one EAC session, than in those that 
received no EAC (75% and 56% respectively, p<0.001). Of the group that underwent EAC and 
were retested, 96 (61%) showed viral suppression, whilst in the group that did not receive 
EAC, 28 (64%) achieved suppression (p=0.729); likewise the proportion re-suppressing did 
not vary according to the number of counseling sessions received. There were no differences 
with regards to age or sex between patients with virological failure and those that showed 
suppression on retesting, but the last CD4 was significantly lower, and the initial VL 
significantly higher, among the failing patients (p=0.011 and 0.027 respectively).   
Final outcomes after routine VL monitoring (table 3) 
Of 288 patients with detectable VL, 86 (30%) never had a follow-up test; four (5%) of these 
patients were changed to second line therapy, 33 (37%) were lost to follow-up, and six (9%) 
died, were hospitalised, stopped ART, or were transferred. The remaining 44 patients (51%) 
are still on first line ART and attending their clinic visits. 
Of the 202 patients with detectable VL who had a follow-up test, 124 (61%) now showed 
viral suppression and were thus maintained on their current regimen. The remaining 78 
patients still had a VL>1000 copies/ml, which equates to virologic failure; of these 11 (14%) 
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were switched to second line therapy after medical review. Forty-one patients (53%) were 
seen by a doctor and re-referred for further adherence counselling, of whom 15 out of 27 
(56%) who underwent a further VL test now showed viral suppression.  Two patients (3%) 
were transferred out or hospitalised; twenty (26%) were not reviewed by a doctor and four 
(4%) were lost to follow-up, and in these cases no treatment decision was made.  
In total 15 patients were switched to second-line therapy, with a median time since first VL 
test of 6.7 months (IQR 5.2-10.2). Eleven of these patients were switched after a follow-up 
VL > 1000copies/ml, which equates to 14% of the patients with virological failure according 
to the WHO algorithm; of these six underwent a further VL test and all six (100%) were now 
virologically suppressed. The remaining four patients who switched to second line were 
switched after a single VL>1000 copies/ml (median time since VL 68 days, IQR 43-92). 
The 288 patients were followed-up for a total of 171 person-years. The rate of switch to 
second line among patients who had a detectable VL was 8.8 per 100 person-years (95%CI 
5.2 – 14.2). Assuming that no patients with undetectable VL were switched to second line 
therapy over an equivalent follow-up period, the estimated rate of switch to second line ART 
in the cohort of VL monitored patients was 1.2 switches per 100 person years (95%CI 0.7– 
2.0). 
Costs 
The total cost of one VL test was $28.33, comprising reagents ($18.76), staff ($4.95), 
consumables ($1.36), transport ($1.20), equipment ($1.18), overheads ($0.50), maintenance 
($0.35) and construction ($0.03). The total cost of one (three session) EAC intervention was 
$1.99. Given that 15% of the cohort had a detectable VL and required EAC and follow-up 
testing, and that 40% of those who had a follow-up test had virological failure and would 
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thus require further counselling and a further VL test that year (whether or not switched to 
second line therapy), it can be seen that VL monitored patients undergo on average 1.21 VL 
tests and 0.21 EAC interventions per patient per year. This equates to a ‘fully-loaded’ cost for 
routine VL monitoring of $35 per patient per year (with EAC contributing $0.42). 
In comparison, the total cost of one CD4 test was $12.30, comprising reagents ($8.08), staff 
($1.08), consumables ($0.29), equipment ($2.24), overheads ($0.18) and maintenance 
($0.04). All CD4 monitored patients are supposed to undergo two CD4 tests per year, 
equivalent to a ‘fully-loaded’ cost for CD4 monitoring  of $25 per patient per year. 
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Discussion 
This study showed that relatively robust routine VL monitoring is achievable in a Ministry of 
Health managed health system, in a setting with high HIV prevalence, at a cost that is 
approximately 40% higher than CD4 monitoring. However, only a small proportion of 
patients who met the WHO 2013 criteria for virologic failure were changed to second line 
therapy. This appeared to be due to clinical suspicion of ongoing adherence problems, lack 
of review by a doctor or loss to follow-up. Given that 60% of patients with initially detectable 
VLs re-suppressed on retesting, for now the greatest impact of VL monitoring is reinforcing 
adherence, rather than early identification of treatment failure.8 For VL monitoring to have 
its full value, programme managers will need to monitor every step in the testing cascade, to 
ensure that ‘leaks’ along the cascade are addressed. 
Although only 2902 (52%) eligible patients were identified as having a VL test over the 12 
month period (through linking their laboratory and clinical records), a further 2220 VL tests 
were sent from clinics over this period but could not be linked to the clinical database. We 
can estimate that 1865 (84%) of these additional tests are likely to have been initial VL tests 
in eligible patients (the review of patient files of patients with detectable VL excluded 16% of 
VL tests that appeared eligible according to lab records). The annual coverage is thus likely 
to be around 86%. There were several other significant ‘leaks in the cascade’, at the point of 
counselling (27%), follow-up testing (30%) and referral of patients with virological failure to 
see a doctor (26% not reviewed). 
The time to receipt of results (<three months), and time to switch to second line therapy 
(<seven months) compare favorably with other studies which generally report much longer 
AC
CE
PT
ED
Copyright   Lippincott Williams & Wilkins. All rights reserved.
 16 
times to treatment switch.11,12 It is likely that the close supervision provided by the MSF 
doctors helped reinforce this cascade. Given that coverage is even then not yet optimal, it 
seems likely that intensified supervision will be required during the implementation phase of 
a national VL roll-out.  
The majority of patients with an initial detectable VL subsequently suppressed (or 
maintained a VL<1000 copies/ml on retesting), as did the majority of patients with 
presumed virologic failure who were re-referred for counselling, which demonstrates the 
value of VL monitoring as a tool to reinforce adherence. It is however difficult to determine 
which element of the EAC intervention had this effect. Given that we observed similar rates 
of suppression among patients that did not receive EAC, it is possible that just being told by 
the nurse that your VL is detectable (and thus that you have been poorly adherent), is an 
equally powerful incentive to improve adherence as a three-month course of EAC. However, 
the proportion of patients who were retested was significantly lower in the group that did 
not undergo EAC; since many patients who were not retested could still have had a high VL, 
the ‘real’ virological outcomes in the non-counseled group may be poorer than our data 
suggest. Randomised controlled trials would be required to accurately determine the 
effectiveness of EAC for improving treatment compliance (and thus virological outcomes). 
The rate of switch to second line therapy of 1.2 per 100 patient years following VL 
monitoring was lower than expected, yet is comparable to that seen in other resource-
limited settings.
3,11,17,18
  Patients identified as being in virological failure had lower CD4 
counts and higher initial VLs than the rest of the study population, and thus are at higher risk 
of developing resistance mutations and complications associated with ongoing viraemia. This 
apparent reluctance to switch to second line therapy may reflect a judgment by the clinician 
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that ongoing poor adherence (not resistance) was the cause of the virological failure; or it 
may represent a ‘holding strategy’, to try to optimise the patient’s adherence before 
changing therapy. Whilst training and supervision could help improve counselling quality and 
clinician confidence regarding second-line therapy, qualitative research might enable a 
better understanding of adherence barriers in those with virological failure, to help ascertain 
which patient groups could benefit most from counselling. Furthermore, it is important to 
ensure an adequate referral pathway for patients with virologic failure, and that doctors are 
confident with interpreting viral load results and second line initiation. 
The strength of this study was the follow up of individual patients through the full process of 
VL monitoring, which gives a reliable vision of the leaks in the cascade. However, patients 
were only followed up for a median of seven months from initial VL test, and some patients 
may have changed treatment regimens after this follow-up period. The analysis of costs 
includes only the testing and counselling process, and does not take into account the 
consequent costs of increased switches to second line therapy associated with viral load 
monitoring, nor the potential costs of additional CD4 and targeted VL tests for 
immunologically-monitored patients with declining CD4 counts. Finally, very few patients in 
this cohort were already on second line therapy; this may reflect the relative ‘youth’ of the 
Swaziland ART programme, and may limit the generalisability of these findings to contexts 
with more mature ART programmes.   
In conclusion, implementation of routine VL monitoring was found to be feasible in a rural 
setting with high HIV prevalence and a large ART cohort, but strong clinical supervision is 
required during the implementation phase to mitigate against leaks in the monitoring 
cascade which will limit its public health impact. In our study EAC appeared to have little 
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impact on likelihood of viral re-suppression, although those who did not receive EAC were 
also less likely to re-test, and the poorest virological outcomes may occur in this group. 
Furthermore, a better understanding of adherence barriers (through qualitative research) 
may help identify which groups are likely to benefit from EAC, and which barriers require 
different types of intervention. Routine VL monitoring resulted in a lower than expected rate 
of switches to second line therapy, which appears to reflect clinician concern that adherence 
problems had not been sufficiently addressed through EAC. Our study found the main 
impact of routine VL monitoring to be a means of reinforcing adherence support, rather than 
increasing use of second-line therapy. 
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Figure Legend:  
 
Figure 1: The routine viral load monitoring cascade, showing ‘leaks’ at each step, Shiselweni, 
Swaziland, 1 Oct 2012 – 31 Mar 2013. 
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Table 1: Proportions and characteristics of clinic ART patients undergoing Routine VL monitoring in Shiselweni, Swaziland, during the 
period of the cohort study (1 Oct 2012 – 31 Mar 2013), and the remaining 6 months of the year. 
 
 Total Eligible for VL
1
 testing 
(1 Oct 2012-31 Mar 2013) 
 Patients not linked 
or not tested
2 
Tested (during study period 
(1 Oct 2012-31 Mar 2013) 
 Tested since study period 
(1 April 2013-30 Sep 2013) 
 P -value 
 N  N (%) N (%)  N (%)   
            
Total  5563  2661 (48%) 1385 (25%)  1517
 
(27%)   
            
Sex           0.986 
Male 2039  974 (48%) 507 (25%)  558 (27%)   
Female 3515
3
  1686 (48%) 874 (25%)  995 (27%)   
            
Age group           0.041 
< 10 (children) 354  193 (55%) 83 (23%)  78 (22%)   
10-19 (adolescents) 277  134 (48%) 76 (27%)  67 (24%)   
20+ (adults) 4932  2334 (47%) 1226 (25%)  1372 (28%)   
            
Median Time on ART
4
 (years) 2.5 (1.6 - 3.7)  2.4 (1.4-3.6) 2.3 (1.5-3.5)  2.4 (1.5-3.5)  0.925
6
 
         
Median CD4 (cells/µl)
4,5
 399(265- 579)  401(259- 600) 395 (266- 561)  383 (268- 556)  0.438
6 
            
WHO stage III/IV
5 
1266  663 (50%) 368 (24%)  331 (26%)  0.143 
            
 
1 
VL=Viral Load 
2  
2628 VL tests were carried out during this time period but are included in the “Not linked /not tested” category because we were unable to link them with patient records.  
3
 Nine patients were recorded as having unknown gender.
 
4  
Presented as median with inter-quartile range in brackets. 
5
Only CD4 counts and WHO Clinical Stages recorded within the previous 12 months of the initial VL are considered here 
6 
P-value refers to non-parametric median test. 
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Table 2: Characteristics of patients with detectable VL, showing the proportions undergoing counselling, receiving a follow-up test, and 
being diagnosed with virological failure, in Shiselweni, Swaziland, 1 Oct 2012 – 31 Mar 2013. 
 
 
 
Detectable VL
1 
 Enhanced Adherence Counselled  Undergoing follow-up testing  Virologic Failure
2 
  N  N (%) P-value
3 
 N (%) P-value
3 
 N (%)
4 
P-value
3 
               
Total  288  210 (73%)   202 (70%)   78 (39%)  
               
Sex      0.626    0.273    0.669 
Male  111  84 (76%)   74 (67%)   30 (41%)  
Female  176  127 (72%)   128 (73%)   48 (38%)  
               
Age group      0.411    0.075    0.822 
< 10 (children)  34  27 (79%)   20 (59%)   12 (60%)  
10-19 (adolescents)  30  23 (77%)   25 (83%)   14 (56%)  
20+ (adults)  184  128 (70%)   136 (74%)   85 (63%)  
            
Median VL1 (log copies/ml)
4
  3.8 (3.1 - 4.6)  3.8 (3.1 - 4.6) 0.647  3.8 (3.1 - 4.6) 0.681  3.9 (3.5 - 4.7) 0.027
5
 
               
Median CD4 (cells/µl) 
6
  407 (196 – 478)  377 (178 – 492) 0.401  357 (221 – 491) 1.000  254 (167 – 394) 0.011 
WHO stage III/IV 
6
  48  39 (81%)   36 (75%)   11 (31%) 0.362 
               
 
1
VL=Viral Load 
2  
Virologic failure defined as a 2
nd
 VL result > 1000 at least 60 days after 1
st
 VL 
3 
 P values refers to comparison of the counselled/retested/virologic failure group, with the not counselled, not retested or virally suppressed groups respectively.  
4
Percentages refers to the subgroup of patients that were retested only 
4
Presented as median with interquartile range in brackets. 
5
Median VL in the virally suppressed group (3.6 (2.9-5.4) 
6  
Only 68 patients had a CD4 cell count, and 188 patients a WHO  clinical stage, recorded within 12 months of the initial VL 
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Table 3: Treatment decisions and results of retesting in the 78 patients with 
virological failure, Shiselweni, Swaziland, 1 Oct 2012 – 31 Mar 2013. 
 
 
Outcome Total Retested Not retested 
  Suppressed (<1000 c/ml) Virologic failure  
Stayed on current ART and recounselled 41 15 (36%) 12 (29%) 14 (34%) 
Switched to 2nd line ART 11 6 (55%) 0 5 (45%) 
Not yet reviewed by Doctor 20 0 0 20 (100%) 
Lost to follow-up 4 0 0 4 (100%) 
Dead, hospitalised or transferred out 2 0 1 (50%) 1 (50%) 
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Figure 1: The routine viral load monitoring cascade, showing ‘leaks’ at each step, 
Shiselweni, Swaziland, 1 Oct 2012 – 31 Mar 2013. 
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